Clinical trials: Carcinoma Breast
Breast Cancer Survivors
Effects of Green Coffee Extract Supplementation on Adropin, Irisin, Vaspine,Systemic Inflammation and Oxidative Stress in Breast Cancer Survivors
To study the effects of green coffee supplement on adropin, irisin, vaspine, systemic inflammation and oxidative stress in breast cancer survivors.50 breast cancer survivors who their treatment is over and referred to follow…
- Trial name
- NCT03395561
- Testing
- green coffee, control
- Where
- Iran
- Volunteers
- 50 people
- Sponsor
- National Nutrition and Food Technology Institute
Breast Cancer
Impact of Intraoperative Neurotization on Sensory Recovery of the Nipple and Breast Skin in Patients Undergoing Nipple Sparing Mastectomy With Immediate Implant-Based Reconstruction: NERSENSE, Prospective Randomized Control Study
The purpose of this clinical trial is to demonstrate the superiority of sensory recovery following sensory nerve coaptation compared with no sensory nerve coaptation in patients undergoing nipple-sparing mastectomy with immediate…
- Trial name
- NEARSENSE (NCT07902661)
- Testing
- Nerve anastomosis
- Volunteers
- 110 people
- Sponsor
- Gangnam Severance Hospital
Metastatic Breast Cancer
Safety and Biodistribution of [68Ga]Ga DOTA-5G in Subjects With Metastatic Breast Cancer (BC)
This is a prospective study using [68Ga]Ga DOTA-5G PET/CT imaging in patients diagnosed with metastatic breast cancer (BC).
- Trial name
- NCT07915297
- Testing
- [68Ga]Ga DOTA-5G
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- Luminance Biosciences Inc
Breast Cancer
Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor
To evaluate the efficacy of tucidinostat-based therapy in hormone receptor-positive metastatic breast cancer patients previously treated with CDK4/6 inhibitor therapy in the real world.
- Trial name
- NCT05276713
- Testing
- Tucidinostat
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Beijing 302 Hospital
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
This phase I trial studies the side effects and best schedule of vaccine therapy with or without sirolimus in treating patients with cancer-testis antigen (NY-ESO-1) expressing solid tumors.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative
- Trial name
- NCT01522820
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer
HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer
The purpose of this study is to determine the safety and immunogenicity of HER-2 pulsed DC1 vaccine in high risk HER-2 high and intermediate expression breast cancers.
- Trial name
- Adjuvant (NCT02063724)
- Testing
- HER-2 pulsed Dendritic Cell Vaccine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Cancer
MRI in Evaluating Early Response to Chemotherapy in Women With Infiltrating Breast Cancer
RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI), may help in learning how well chemotherapy works to kill breast cancer cells and allow doctors to plan better treatment.
- Trial name
- ISNA-Sein (NCT00462696)
- Testing
- Neoadjuvant chemotherapy
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Institut Bergonié
Colorectal Cancer, Breast Carcinoma
FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer
This trial is a first in human (FIH) clinical trial in patients with Colorectal cancer (CRC) after failure of at least three lines of previous therapy aiming to evaluate safety and efficacy of CC-3, a bispecific antibody (bsAb)…
- Conditions
- Colorectal Cancer, Breast Carcinoma, Sarcoma, Penile Carcinoma
- Trial name
- CoRe_CC-3 (NCT05999396)
- Testing
- Administration of CC-3
- Where
- Germany
- Volunteers
- 89 people
- Sponsor
- German Cancer Research Center
Breast Cancer, Breast Cancer Stage II
Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer
This study will evaluate the immune-priming effects of stereotactic body radiation therapy (SBRT) regimen coupled with two injections of pembrolizumab in high-risk primary breast carcinoma prior to neoadjuvant chemotherapy.
- Conditions
- Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Invasive
- Trial name
- BRINK (NCT07188246)
- Testing
- Radiation, Pembrolizumab (KEYTRUDA®)
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Metastatic Breast Cancer, Recurrent Breast Cancer
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
This is a phase Ib/II exploratory study. Phase Ib includes the dose escalation and expansion study of monotherapy, as well as the dose escalation study of combination therapy.
- Conditions
- Metastatic Breast Cancer, Recurrent Breast Cancer, Advanced Malignancies
- Trial name
- NCT06202261
- Testing
- TQB2930 for injection, Paclitaxel for injection (albumin-bound), TQB3616 capsule
- Where
- 2 sites in China
- Volunteers
- 154 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer
Neo-Adjuvant Study in Triple Negative Breast Cancer Patients
Ixabepilone and capecitabine combination has demonstrated to be an active regimen in patients with metastatic breast cancer after failing other treatments.
- Trial name
- ICE (NCT01097642)
- Testing
- Cetuximab, Ixabepilone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- The Methodist Hospital Research Institute
Breast Cancer
A Real-World Study of Early Breast Cancer Patients Eligible for Treatment With CDK4/6 Inhibitors
The aim of this study was to describe treatment patterns, patient characteristics and clinical outcomes among hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) early breast cancer (eBC)…
- Trial name
- LEEWARD (NCT07647042)
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer, Liver Cancer
Evaluation of Novel Cone-Beam CT for Guidance and Adaptation of Precision Radiotherapy
This is a feasibility study investigating the image quality of a new, high-performance cone beam CT (CBCT) used for on-couch imaging during radiotherapy treatments.
- Conditions
- Lung Cancer, Liver Cancer, Breast Cancer, Other Cancer
- Trial name
- NCT05176860
- Testing
- CBCT Imaging
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- Varian, a Siemens Healthineers Company
Breast Cancer
Physical Activity and Breast Cancer Risk in Postmenopausal Women:the SHAPE Study
Purpose of the SHAPE study is to examine the effects of an 1-year exercise programme on endogenous hormone levels associated with breast cancer among sedentary postmenopausal women and whether a decrease in intra-abdominal fat is…
- Trial name
- NCT00359060
- Testing
- Physical activity
- Where
- Netherlands
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- UMC Utrecht
Postoperative Acute Pain, Breast Cancer
IPP-PSP Block vs. SPSIPB in Breast Surgery
This prospective, randomized clinical study aims to compare the analgesic efficacy of the interpectoral-pectoserratus plane block and the serratus posterior superior intercostal plane block for postoperative pain management in…
- Conditions
- Postoperative Acute Pain, Breast Cancer, Regional Anesthesia
- Trial name
- NCT07246720
- Testing
- Interpectoral-Pectoserratus Plane Block, Serratus Posterior Superior Intercostal Plane Block
- Where
- Turkey (Türkiye)
- Volunteers
- 70 people
- Sponsor
- Zonguldak Bulent Ecevit University
Secondary Lymphedema
Hyperbaric Oxygen Therapy to Reduce Lymphedema After Breast Cancer -an Explorative Clinical Trial
The purpose of this study is to examine if pressurechamber treatment (HBOT) can reduce early stages of breast cancer related lymphedema, and to explore the mechanisms involved in the disease progress.
- Trial name
- HBOT-LYCA (NCT02895724)
- Testing
- Medical Oxygen
- Volunteers
- 20 people
- Sponsor
- Danish Cancer Society
Breast Cancer Invasive
Ultrasound Imaging, Spectroscopy and Ultrasound Imaging of Vascular Blood Flow as Early Indicators of Breast Cancer Response to Neoadjuvant Treatment.
We have previously demonstrated that high-frequency ultrasound and spectroscopy, and recently conventional-frequency ultrasound and spectroscopy may be used to detect cell death in vitro, in situ and in vivo.
- Trial name
- NCT00437879
- Where
- Canada
- Volunteers
- 600 people
- Sponsor
- Sunnybrook Health Sciences Centre
Triple Negative Breast Neoplasms
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy and pembrolizumab vs placebo as adjuvant therapy in participants…
- Trial name
- NCT03036488
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 193 sites in United States, Australia and 19 more
- Volunteers
- 1,174 people
- Sponsor
- Merck Sharp & Dohme LLC
Triple Negative Breast Neoplasms
"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer
Neoadjuvant treatment is an important part of the treatment strategy for locally advanced TNBC having established a positive and significant correlation of pathologic Complete Response (pCR) with long-term clinical benefit such…
- Trial name
- neoBREASTIM (NCT06067061)
- Testing
- Atezolizumab + RP1
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Institut Curie
Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with unresectable, locally advanced, or metastatic solid tumors…
- Conditions
- Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT07623642
- Testing
- GV20-0251, anti-PD-1 monoclonal antibodies
- Where
- 2 sites in China
- Volunteers
- 227 people
- Sponsor
- GV20 Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.